Immutep Limited/ US45257L1089 /
2024-07-26 8:26:15 PM | Chg. +0.01 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
2.14USD | +0.23% | 445 Turnover: 960.30 |
-Bid Size: - | -Ask Size: - | 2.17 | 2.14 |
GlobeNewswire
06-25
Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Mol...
GlobeNewswire
06-05
Immutep successfully completes institutional placement and institutional component of entitlement of...
GlobeNewswire
06-03
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pe...
GlobeNewswire
05-15
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024
GlobeNewswire
05-02
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoin...
GlobeNewswire
04-18
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761
GlobeNewswire
04-17
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registra...
GlobeNewswire
01-04
First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urot...
GlobeNewswire
2023-12-21
Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic No...
GlobeNewswire
2023-11-09
Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metast...
GlobeNewswire
2023-11-06
Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIP...
GlobeNewswire
2023-11-03
Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cance...
GlobeNewswire
2023-10-24
Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023